NCT04822688

Analysis of Cell Count, Viability, and Immunogenicity of Discarded Newly Diagnosed Glioblastoma Tissue or Solid Tumor Tissues

Analysis of Cell Count, Viability, and Immunogenicity of Deidentified Discarded Newly Diagnosed Glioblastoma Tissue and More Broadly Other Newly Diagnosed Solid Tumor Tissues From the Operating Room

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 141 (actual)
• Sponsor: Thomas Jefferson University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study examines tumor tissues and blood samples to aid in the development of therapies for brain cancer and other solid tumors. Studying samples of blood and tissue from patients with glioblastoma or other solid tumor in the laboratory may help doctors understand brain tumors and better inform future treatments.

Detailed description

PRIMARY OBJECTIVES: I. Assessment of cell yield and percentage of viable cells upon tissue receipt at the cell processing facility. II. Obtain discarded tumor tissue from surgical resections for further studies to aid in development of future therapies for glioblastoma (GBM) and other solid tumors. SECONDARY OBJECTIVE: I. Assessment of cell yield and percentage of viable cells from other solid tumor cells shipped to the cell processing facility. EXPLORATORY OBJECTIVE: I. An additional line of inquiry will be devoted to scientific exploration of the product's immunogenicity looking at important variables in the course of manufacture. OUTLINE: Patients undergo collection of tissue sample during surgery. Patients also undergo collection of blood sample.

Conditions

• Glioblastoma
• Malignant Solid Neoplasm

Interventions

Type	Name	Description
PROCEDURE	Biospecimen Collection	Undergo collection of tissue and blood samples

Timeline

• Start date: 2021-02-03
• Primary completion: 2025-06-30
• Completion: 2025-06-30
• First posted: 2021-03-30
• Last updated: 2026-02-10

Locations

1 site across 1 country: United States